Table 4. Mean and median percentage changes in secondary endpoint lipid parameters from Phase 3 study–derived baseline to Week 60 LOCF of extension study.

Variable Statistic	Week 60 LOCF			P-Valuea
	Observed Value	Observed Change	Percent Change
Total Cholesterol (mg/dL), N	5	5	5
Mean (SD)	203.6 (58.46)	−71.2 (36.28)	−26.53 (13.967)
Median	178.0	−77.5	−33.18
(Min., Max.)	(142, 269)	(−102, −11)	(−38.1, −3.8)
[95% CI]	[131.0, 276.2]	[−116.2, −26.2]	[−43.88, −9.19]	0.012
apoB (mg/dL) N	2	2	2
Mean (SD)	98.5 (38.89)	−39.5 (28.28)	−29.50 (22.763)
Median	98.5	−39.5	−29.50
(Min., Max.)	(71, 126)	(−60, −20)	(−45.6, −13.4)
[95% CI]	[−250.9, 447.9]	[−293.6, 214.6]	[−234.02, 175.02]	NS
Triglycerides (mg/dL), N	5	5	5
Mean (SD)	41.2 (13.92)	−50.1 (18.48)	−54.75 (12.248)
Median	41.0	−49.5	−50.24
(Min., Max.)	(19, 54)	(−79, −28)	(−68.9, −40.6)
[95% CI]	[23.9, 58.5]	[−73.1, −27.1]	[−69.96, −39.54]	0.004
Non-HDL-C (mg/dL), N	5	5	5
Mean (SD)	140.4 (53.98)	−80.6 (34.92)	−37.45 (17.114)
Median	112.0	−85.0	−40.83
(Min., Max.)	(92, 201)	(−112, −27)	(−54.9, −11.8)
[95% CI]	[73.4, 207.4]	[−124.0, −37.2]	[−58.70, −16.20]	0.007
Lp(a) (nmol/L), N	2	2	2
Mean (SD)	25.2 (0.21)	−36.9 (4.74)	−59.32 (2.906)
Median	25.2	−36.9	−59.32
(Min., Max.)	(25, 25)	(−40, −34)	(−61.4, −57.3)
[95% CI]	[23.2, 27.1]	[−79.4, 5.7]	[−85.42, −33.21]	NS
HDL-C (mg/dL), N	5	5	5
Mean (SD)	63.2 (12.30)	9.4 (7.06)	17.04 (14.036)
Median	66.0	10.0	15.63
(Min., Max.)	(42, 74)	(−2, 17)	(−3.4, 32.0)
[95% CI]	[47.9, 78.5]	[0.6, 18.2]	[−0.39, 34.47]	0.041
apoA1 (mg/dL), N	2	2	2
Mean (SD)	131.0 (26.87)	−1.5 (32.53)	−0.61 (24.523)
Median	131.0	−1.5	−0.61
(Min., Max.)	(112, 150)	(−25, 22)	(−17.9, 16.7)
[95% CI]	[−110.4, 372.4]	[−293.7, 290.7]	[−220.94, 219.72]	NS

apoA1, apolipoprotein A1; apoB, apolipoprotein B; CI, confidence interval; HDL-C, high-density lipoprotein cholesterol; LOCF, last observation carried forward; Lp(a), lipoprotein(a); non-HDL-C, non-high-density lipoprotein cholesterol; SD, standard deviation; NS, not significant

^aP-value from paired t-test